Yu YF - Search Results

1

[Incidence, time trend, survival, and predictive factors of lung cancer in Shanghai populations].

Liao ML, Chen ZW, Zheng Y, Wu CX, Lu S, Yu YF, Jian H, Cheng BJ. Liao ML, et al. Among authors: yu yf. Zhonghua Yi Xue Za Zhi. 2007 Jul 17;87(27):1876-80. Zhonghua Yi Xue Za Zhi. 2007. PMID: 17923007 Chinese.

2

[Advances in the molecular target therapy in lung cancer].

Lu S, Yu YF, Li Zi. Lu S, et al. Among authors: yu yf. Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):701-4. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 16438897 Chinese. No abstract available.

3

Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.

Li Z, Yu Y, Lu J, Luo Q, Wu C, Liao M, Zheng Y, Ai X, Gu L, Lu S. Li Z, et al. J Thorac Oncol. 2009 Jun;4(6):702-9. doi: 10.1097/JTO.0b013e3181a5269d. J Thorac Oncol. 2009. PMID: 19404215 Free article.

4

Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer.

Yao X, Jiang H, Zhang C, Wang H, Yang L, Yu Y, Yu J, Shi B, Shen Z, Gao H, Chen Z, Tian S, Lu S, Li Z, Gu J. Yao X, et al. Biomarkers. 2010 Mar;15(2):128-34. doi: 10.3109/13547500903325662. Biomarkers. 2010. PMID: 19839718

5

[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].

Zhang YF, Yu YF, Lu S. Zhang YF, et al. Among authors: yu yf. Zhonghua Yi Xue Za Zhi. 2009 Jun 9;89(22):1544-8. Zhonghua Yi Xue Za Zhi. 2009. PMID: 19953882 Chinese.

6

Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population.

Niu X, Chen Z, Shen S, Liu Y, Zhou D, Zhang J, Li Z, Yu Y, Liao M, Lu S, He L. Niu X, et al. J Thorac Oncol. 2010 May;5(5):658-66. doi: 10.1097/JTO.0b013e3181d5e447. J Thorac Oncol. 2010. PMID: 20234319 Free article.

7

Functional roles of PC-PLC and Cdc20 in the cell cycle, proliferation, and apoptosis.

Chen Z, Yu Y, Fu D, Li Z, Niu X, Liao M, Lu S. Chen Z, et al. Cell Biochem Funct. 2010 Jun;28(4):249-57. doi: 10.1002/cbf.1634. Cell Biochem Funct. 2010. PMID: 20517887

8

[Perioperative chemotherapy of stage III N2 non-small cell lung cancer.].

Lu S, Yu Y. Lu S, et al. Zhongguo Fei Ai Za Zhi. 2008 Oct 20;11(5):652-6. doi: 10.3779/j.issn.1009-3419.2008.05.004. Zhongguo Fei Ai Za Zhi. 2008. PMID: 20738906 Free article. Chinese. No abstract available.

9

Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancer.

Zhang J, Niu XM, Liao ML, Liu Y, Sha HF, Zhao Y, Yu YF, Tan Q, Xiang JQ, Fang J, Lv DD, Li XB, Lu S, Chen HQ. Zhang J, et al. Among authors: yu yf. Oncol Rep. 2010 Nov;24(5):1185-92. doi: 10.3892/or_00000971. Oncol Rep. 2010. PMID: 20878109

10

A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.

Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S. Yu YF, et al. Chemotherapy. 2010;56(6):472-7. doi: 10.1159/000321016. Epub 2010 Nov 23. Chemotherapy. 2010. PMID: 21099219

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters